NEW QUINOLINE COMPOUNDS Russian patent published in 2023 - IPC C07D401/14 C07D403/02 C07D403/14 C07D405/14 C07D413/14 C07D417/14 C07D498/08 A61K31/435 A61K31/4709 A61K31/5377 A61P35/00 

FIELD: organic chemistry; pharmaceuticals.

SUBSTANCE: group of inventions is aimed at the prevention and treatment of cancer mediated by FGFR kinase. The following is disclosed: a compound of formula I, wherein each of A₁, A₂ and A₃ independently represents a carbon atom; C₁ represents hydrogen or C_1-4alkyl; C₂ represents hydrogen or C_1-4 alkyl; or C₁ and C₂ taken together form a C_3-6cycloalkyl together with the carbon atom to which they are attached; Y is a single bond, -O-, C(=O) or NR^y; R^y represents hydrogen or C_1-4alkyl; each R^a is independently hydrogen, C_1-6alkyl, halogen, C_1-6alkyl, or halogen; na represents an integer equal to 1; each R^b is independently hydrogen or halogen; nb represents an integer equal to 1; D is a 5- or 6-membered aromatic or non-aromatic heterocyclyl containing either 1 or 2 heteroatoms selected from N or O, or a bridged heterocyclyl containing 1 or 2 heteroatoms selected from N or O, wherein the said heterocyclyl is optionally substituted with 1-4 substituents R^c; each R^c independently represents an oxo-, C_1-6alkyl, halogen C_1-6alkyl, halogen C_1-6alkoxy group, carboxyl group, HOOC-C_1-6alkyl-, C_1-6alkyl, substituted -C (=O)-OC_1-6alkyl, or C_1-6alkyl-OC(=O)-; B is a 5-6-membered heterocyclyl containing either 1 or 2 heteroatoms selected from N, O or S, the said heterocyclyl being optionally substituted with 1 R substituent; each R independently represents a C_1-6alkyl, a C_1-6alkoxy group or a C_3-6cycloalkyl; or a pharmaceutically acceptable salt thereof. Besides, a pharmaceutical composition having FGFR (Fibroblast Growth Factor Receptor) inhibitory activity is disclosed, containing an effective amount of the above compound, the use of a compound of formula I for the manufacture of a medicament for the prevention or treatment of a disease state or condition mediated by an FGFR kinase, the use of a compound of formula I for the manufacture of a medicinal product for the prevention or treatment of cancer mediated by FGFR kinase.

EFFECT: group of inventions provides effective treatment of oncological diseases mediated by FGFR kinase.

22 cl, 2 tbl, 7 ex